David A. Siegel T Scan Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 49,000 shares of TCRX stock, worth $82,810. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,000Holding current value
$82,810% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding TCRX
# of Institutions
92Shares Held
39.8MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.36MShares$9.05 Million2.73% of portfolio
-
Bvf Inc San Francisco, CA4.89MShares$8.26 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$7.54 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.5MShares$5.92 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$4.71 Million0.05% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $32M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...